IgD cross-linking induces gene expression profiling changes and enhances apoptosis in chronic lymphocytic leukemia cells

Leukemia Research

Volumn 37, Issue 4, 2013, Pages 455-462

  Tavolaro, Simona ^a   Peragine, Nadia ^a   Chiaretti, Sabina ^a   Ricciardi, Maria Rosaria ^a   Raponi, Sara ^a   Messina, Monica ^a   Santangelo, Simona ^a   Marinelli, Marilisa ^a   Di Maio, Valeria ^a   Mauro, Francesca Romana ^a   Del Giudice, Ilaria ^a   Foà, Robin ^a   Guarini, Anna ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antigenic stimulation; Apoptosis; B cell receptor; Cell cycle; CLL; Microarray

Indexed keywords

B LYMPHOCYTE RECEPTOR; IMMUNOGLOBULIN D; IMMUNOGLOBULIN M;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL ADHESION; CELL DEATH; CELL DIFFERENTIATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; PRIORITY JOURNAL; PROTEIN CROSS LINKING; SIGNAL TRANSDUCTION; UPREGULATION;

AGED; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOGLOBULIN D; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 84875375348     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.12.019     Document Type: Article

References (32)

1. Chiorazzi N., Rai K.R., Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005, 352:804-815.
2. Rozman C., Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995, 333:1052-1057.
3. Messmer B.T., Messmer D., Allen S.L., Kolitz J.E., Kudalkar P., Cesar D., et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005, 115:755-764.
4. Damle R.N., Wasil T., Fais F., Ghiotto F., Valetto A., Allen S.L., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94:1840-1847.
5. Hamblin T.J., Davis Z., Gardiner A., Oscier D.G., Stevenson F.K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94:1848-1854.
6. Rosenwald A., Alizadeh A.A., Widhopf G., Simon R., Davis R.E., Yu X., et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001, 194:1639-1647.
7. Klein U., Tu Y., Stolovitzky G.A., Mattioli M., Cattoretti G., Husson H., et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001, 194:1625-1638.
8. Stamatopoulos K., Belessi C., Moreno C., Boudjograh M., Guida G., Smilevska T., et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007, 109:259-270.
9. Chiorazzi N., Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol 2003, 21:841-894.
10. Zupo S., Isnardi L., Megna M., Massara R., Malavasi F., Dono M., et al. CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. Blood 1996, 88:1365-1374.
11. Lanham S., Hamblin T., Oscier D., Ibbotson R., Stevenson F., Packham G. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 2003, 101:1087-1093.
12. Allsup D.J., Kamiguti A.S., Lin K., Sherrington P.D., Matrai Z., Slupsky J.R., et al. B-cell receptor translocation to lipid rafts and associated signaling differ between prognostically important subgroups of chronic lymphocytic leukemia. Cancer Res 2005, 65:7328-7337.
13. Guarini A., Chiaretti S., Tavolaro S., Maggio R., Peragine N., Citarella F., et al. BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. Blood 2008, 112:782-792.
14. Gobessi S., Laurenti L., Longo P.G., Sica S., Leone G., Efremov D.G. ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood 2007, 109:2032-2039.
15. Muzio M., Apollonio B., Scielzo C., Frenquelli M., Vandoni I., Boussiotis V., et al. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood 2008, 112:188-195.
16. Zupo S., Massara R., Dono M., Rossi E., Malavasi F., Cosulich M.E., et al. Apoptosis or plasma cell differentiation of CD38-positive B-chronic lymphocytic leukemia cells induced by cross-linking of surface IgM or IgD. Blood 2000, 95:1199-1206.
17. Mockridge C.I., Potter K.N., Wheatley I., Neville L.A., Packham G., Stevenson F.K. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood 2007, 109:4424-4431.
18. Morabito F., Cutrona G., Gentile M., Fabbi M., Matis S., Colombo M., et al. Prognostic relevance of in vitro response to cell stimulation via surface IgD in binet stage a CLL. Br J Haematol 2010, 149:160-163.
19. Guarini A., Gaidano G., Mauro F.R., Capello D., Mancini F., De Propris M.S., et al. Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. Blood 2003, 102:1035-1041.
20. Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A., Newcomb E.W., et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1991, 88:5413-5417.
21. Crespo M., Bosch F., Villamor N., Bellosillo B., Colomer D., Rozman M., et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003, 348:1764-1775.
22. Gentile M., Mauro F.R., Calabrese E., De Propris M.S., Giammartini E., Mancini F., et al. The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience. Br J Haematol 2005, 130:549-557.
23. Herishanu Y., Pérez-Galán P., Liu D., Biancotto A., Pittaluga S., Vire B., et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011, 117:563-574.
24. Li C., Wong W.H. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 2001, 98:31-36.
25. Eisen M.B., Spellman P.T., Brown P.O., Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998, 95:14863-14868.
26. Ricciardi M.R., Petrucci M.T., Gregorj C., Ariola C., Lemoli R.M., Fogli M., et al. Reduced susceptibility to apoptosis correlates with kinetic quiescence in disease progression of chronic lymphocytic leukaemia. Br J Haematol 2001, 113:391-399.
27. Darzynkiewicz Z., Bruno S., Del Bino G., Gorczyca W., Hotz M.A., Lassota P., et al. Features of apoptotic cells measured by flow cytometry. Cytometry 1992, 13:795-808.
28. Peckham D., Andersen-Nissen E., Finkelman F.D., Stunz L.L., Ashman R.F. Difference in apoptosis induction between surface IgD and IgM. Int Immunol 2000, 13:285-295.
29. Calpe E., Codony C., Baptista M.J., Abrisqueta P., Del Carpio C., Purroy N., et al. ZAP-70 enhances migration of malignant B lymphocytes towards CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation. Blood 2011, 118:4401-4410.
30. Stevenson F.K., Krysov S., Davies A.J., Steele A.J., Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011, 118:4313-4320.
31. Burger J.A. Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia. Curr Hematol Malig Rep 2012, 7:26-33.
32. Flinn I.W., Schreeder M.T., Wagner-Johnston N., Boccia R.V., Leonard J.P., Coutre S.E., et al. A phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ, in combination with rituximab and/or bendamustine in patients with relapsed or refractory B-cell malignancies [abstract]. Blood (ASH Annual Meeting Abstracts) 2010, 116:2832. [Abstract 2832].